XERIS BIOPHARMA HOLDINGS, INC. Net Income (Loss) Available to Common Stockholders, Basic
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Net Income (Loss) Available to Common Stockholders, Basic of $2.23 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-05-07
- XERIS BIOPHARMA HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was $2.23M.
- XERIS BIOPHARMA HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was $11.08M.
- XERIS BIOPHARMA HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was $621.00K.
- XERIS BIOPHARMA HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-03-31 was -$9.22M.
- XERIS BIOPHARMA HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was $554.00K.
- XERIS BIOPHARMA HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$54.84M.
- XERIS BIOPHARMA HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$62.26M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-03-31 | $2.23M 10-Q · filed 2026-05-07 | $13.31M derived: sum of 2 quarters · filed 2026-05-07 | $13.94M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2025-12-31 | $11.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $11.70M derived: sum of 2 quarters · filed 2026-03-02 | $554.00K 10-K · filed 2026-03-02 | |
| 2025-09-30 | $621.00K 10-Q · filed 2025-11-06 | -$10.53M 10-Q · filed 2025-11-06 | ||
| 2025-03-31 | -$9.22M 10-Q · filed 2026-05-07 | -$14.33M derived: sum of 2 quarters · filed 2026-05-07 | -$30.07M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$5.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$20.85M derived: sum of 2 quarters · filed 2026-03-02 | -$54.84M 10-K · filed 2026-03-02 | |
| 2024-09-30 | -$15.74M 10-Q · filed 2025-11-06 | -$49.72M 10-Q · filed 2025-11-06 | ||
| 2023-12-31 | -$62.26M 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |